世界の心筋症治療薬市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Cardiomyopathy Medication Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-3973
• 出版社/出版日：QYResearch / 2021年6月
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、107ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医療

• 販売価格（消費税別）

Single User	￥546,000 (USD3,900)	▷ お問い合わせ
Multi User	￥819,000 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査レポートでは、心筋症治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（抗凝固剤、抗不整脈剤、抗高血圧剤、心筋配糖体、その他）、用途別市場規模（病院、診療所、ホームケア、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。
・市場概要
・心筋症治療薬の市場動向
・企業の競争状況、市場シェア
・心筋症治療薬の種類別市場規模と予測2016-2027（抗凝固剤、抗不整脈剤、抗高血圧剤、心筋配糖体、その他）
・心筋症治療薬の用途別市場規模と予測2016-2027（病院、診療所、ホームケア、その他）
・心筋症治療薬の北米市場規模2016-2027（アメリカ、カナダ）
・心筋症治療薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等）
・心筋症治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・心筋症治療薬の中南米市場規模2016-2027（メキシコ、ブラジル）
・心筋症治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（Pfizer、Roche、Sanofi、AstraZeneca、Merck、Teva Pharmaceutical、Johnson & Johnson、PhaseBio Pharmaceuticals、Capricor Therapeutics、MyoKardia）
・結論

Cardiomyopathy is a group of diseases that affect the heart muscle. Early on there may be few or no symptoms. As the disease worsens, shortness of breath, feeling tired, and swelling of the legs may occur, due to the onset of heart failure. An irregular heart beat and fainting may occur. Those affected are at an increased risk of sudden cardiac death.

Market Analysis and Insights: Global Cardiomyopathy Medication Market
The global Cardiomyopathy Medication market size is projected to reach US$ 528.4 million by 2027, from US$ 428.1 million in 2020, at a CAGR of 2.6% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Cardiomyopathy Medication market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Cardiomyopathy Medication market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Cardiomyopathy Medication market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Cardiomyopathy Medication market.

Global Cardiomyopathy Medication Scope and Market Size
Cardiomyopathy Medication market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Cardiomyopathy Medication market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Anticoagulants
Antiarrhythmics
Anti-Hypertensives
Cardiac Glycosides
Others

Segment by Application
Hospitals
Clinics
Homecare
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Pfizer
Roche
Sanofi
AstraZeneca
Merck
Teva Pharmaceutical
Johnson & Johnson
PhaseBio Pharmaceuticals
Capricor Therapeutics
MyoKardia

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cardiomyopathy Medication Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Anticoagulants
1.2.3 Antiarrhythmics
1.2.4 Anti-Hypertensives
1.2.5 Cardiac Glycosides
1.2.6 Others
1.3 Market by Application
1.3.1 Global Cardiomyopathy Medication Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Homecare
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Cardiomyopathy Medication Market Perspective (2016-2027)
2.2 Cardiomyopathy Medication Growth Trends by Regions
2.2.1 Cardiomyopathy Medication Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Cardiomyopathy Medication Historic Market Share by Regions (2016-2021)
2.2.3 Cardiomyopathy Medication Forecasted Market Size by Regions (2022-2027)
2.3 Cardiomyopathy Medication Industry Dynamic
2.3.1 Cardiomyopathy Medication Market Trends
2.3.2 Cardiomyopathy Medication Market Drivers
2.3.3 Cardiomyopathy Medication Market Challenges
2.3.4 Cardiomyopathy Medication Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Cardiomyopathy Medication Players by Revenue
3.1.1 Global Top Cardiomyopathy Medication Players by Revenue (2016-2021)
3.1.2 Global Cardiomyopathy Medication Revenue Market Share by Players (2016-2021)
3.2 Global Cardiomyopathy Medication Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Cardiomyopathy Medication Revenue
3.4 Global Cardiomyopathy Medication Market Concentration Ratio
3.4.1 Global Cardiomyopathy Medication Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cardiomyopathy Medication Revenue in 2020
3.5 Cardiomyopathy Medication Key Players Head office and Area Served
3.6 Key Players Cardiomyopathy Medication Product Solution and Service
3.7 Date of Enter into Cardiomyopathy Medication Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Cardiomyopathy Medication Breakdown Data by Type
4.1 Global Cardiomyopathy Medication Historic Market Size by Type (2016-2021)
4.2 Global Cardiomyopathy Medication Forecasted Market Size by Type (2022-2027)

5 Cardiomyopathy Medication Breakdown Data by Application
5.1 Global Cardiomyopathy Medication Historic Market Size by Application (2016-2021)
5.2 Global Cardiomyopathy Medication Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Cardiomyopathy Medication Market Size (2016-2027)
6.2 North America Cardiomyopathy Medication Market Size by Type
6.2.1 North America Cardiomyopathy Medication Market Size by Type (2016-2021)
6.2.2 North America Cardiomyopathy Medication Market Size by Type (2022-2027)
6.2.3 North America Cardiomyopathy Medication Market Size by Type (2016-2027)
6.3 North America Cardiomyopathy Medication Market Size by Application
6.3.1 North America Cardiomyopathy Medication Market Size by Application (2016-2021)
6.3.2 North America Cardiomyopathy Medication Market Size by Application (2022-2027)
6.3.3 North America Cardiomyopathy Medication Market Size by Application (2016-2027)
6.4 North America Cardiomyopathy Medication Market Size by Country
6.4.1 North America Cardiomyopathy Medication Market Size by Country (2016-2021)
6.4.2 North America Cardiomyopathy Medication Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Cardiomyopathy Medication Market Size (2016-2027)
7.2 Europe Cardiomyopathy Medication Market Size by Type
7.2.1 Europe Cardiomyopathy Medication Market Size by Type (2016-2021)
7.2.2 Europe Cardiomyopathy Medication Market Size by Type (2022-2027)
7.2.3 Europe Cardiomyopathy Medication Market Size by Type (2016-2027)
7.3 Europe Cardiomyopathy Medication Market Size by Application
7.3.1 Europe Cardiomyopathy Medication Market Size by Application (2016-2021)
7.3.2 Europe Cardiomyopathy Medication Market Size by Application (2022-2027)
7.3.3 Europe Cardiomyopathy Medication Market Size by Application (2016-2027)
7.4 Europe Cardiomyopathy Medication Market Size by Country
7.4.1 Europe Cardiomyopathy Medication Market Size by Country (2016-2021)
7.4.2 Europe Cardiomyopathy Medication Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Cardiomyopathy Medication Market Size (2016-2027)
8.2 Asia-Pacific Cardiomyopathy Medication Market Size by Type
8.2.1 Asia-Pacific Cardiomyopathy Medication Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Cardiomyopathy Medication Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Cardiomyopathy Medication Market Size by Type (2016-2027)
8.3 Asia-Pacific Cardiomyopathy Medication Market Size by Application
8.3.1 Asia-Pacific Cardiomyopathy Medication Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Cardiomyopathy Medication Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Cardiomyopathy Medication Market Size by Application (2016-2027)
8.4 Asia-Pacific Cardiomyopathy Medication Market Size by Region
8.4.1 Asia-Pacific Cardiomyopathy Medication Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Cardiomyopathy Medication Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Cardiomyopathy Medication Market Size (2016-2027)
9.2 Latin America Cardiomyopathy Medication Market Size by Type
9.2.1 Latin America Cardiomyopathy Medication Market Size by Type (2016-2021)
9.2.2 Latin America Cardiomyopathy Medication Market Size by Type (2022-2027)
9.2.3 Latin America Cardiomyopathy Medication Market Size by Type (2016-2027)
9.3 Latin America Cardiomyopathy Medication Market Size by Application
9.3.1 Latin America Cardiomyopathy Medication Market Size by Application (2016-2021)
9.3.2 Latin America Cardiomyopathy Medication Market Size by Application (2022-2027)
9.3.3 Latin America Cardiomyopathy Medication Market Size by Application (2016-2027)
9.4 Latin America Cardiomyopathy Medication Market Size by Country
9.4.1 Latin America Cardiomyopathy Medication Market Size by Country (2016-2021)
9.4.2 Latin America Cardiomyopathy Medication Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Cardiomyopathy Medication Market Size (2016-2027)
10.2 Middle East & Africa Cardiomyopathy Medication Market Size by Type
10.2.1 Middle East & Africa Cardiomyopathy Medication Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Cardiomyopathy Medication Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Cardiomyopathy Medication Market Size by Type (2016-2027)
10.3 Middle East & Africa Cardiomyopathy Medication Market Size by Application
10.3.1 Middle East & Africa Cardiomyopathy Medication Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Cardiomyopathy Medication Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Cardiomyopathy Medication Market Size by Application (2016-2027)
10.4 Middle East & Africa Cardiomyopathy Medication Market Size by Country
10.4.1 Middle East & Africa Cardiomyopathy Medication Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Cardiomyopathy Medication Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Cardiomyopathy Medication Introduction
11.1.4 Pfizer Revenue in Cardiomyopathy Medication Business (2016-2021)
11.1.5 Pfizer Recent Development
11.2 Roche
11.2.1 Roche Company Details
11.2.2 Roche Business Overview
11.2.3 Roche Cardiomyopathy Medication Introduction
11.2.4 Roche Revenue in Cardiomyopathy Medication Business (2016-2021)
11.2.5 Roche Recent Development
11.3 Sanofi
11.3.1 Sanofi Company Details
11.3.2 Sanofi Business Overview
11.3.3 Sanofi Cardiomyopathy Medication Introduction
11.3.4 Sanofi Revenue in Cardiomyopathy Medication Business (2016-2021)
11.3.5 Sanofi Recent Development
11.4 AstraZeneca
11.4.1 AstraZeneca Company Details
11.4.2 AstraZeneca Business Overview
11.4.3 AstraZeneca Cardiomyopathy Medication Introduction
11.4.4 AstraZeneca Revenue in Cardiomyopathy Medication Business (2016-2021)
11.4.5 AstraZeneca Recent Development
11.5 Merck
11.5.1 Merck Company Details
11.5.2 Merck Business Overview
11.5.3 Merck Cardiomyopathy Medication Introduction
11.5.4 Merck Revenue in Cardiomyopathy Medication Business (2016-2021)
11.5.5 Merck Recent Development
11.6 Teva Pharmaceutical
11.6.1 Teva Pharmaceutical Company Details
11.6.2 Teva Pharmaceutical Business Overview
11.6.3 Teva Pharmaceutical Cardiomyopathy Medication Introduction
11.6.4 Teva Pharmaceutical Revenue in Cardiomyopathy Medication Business (2016-2021)
11.6.5 Teva Pharmaceutical Recent Development
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Company Details
11.7.2 Johnson & Johnson Business Overview
11.7.3 Johnson & Johnson Cardiomyopathy Medication Introduction
11.7.4 Johnson & Johnson Revenue in Cardiomyopathy Medication Business (2016-2021)
11.7.5 Johnson & Johnson Recent Development
11.8 PhaseBio Pharmaceuticals
11.8.1 PhaseBio Pharmaceuticals Company Details
11.8.2 PhaseBio Pharmaceuticals Business Overview
11.8.3 PhaseBio Pharmaceuticals Cardiomyopathy Medication Introduction
11.8.4 PhaseBio Pharmaceuticals Revenue in Cardiomyopathy Medication Business (2016-2021)
11.8.5 PhaseBio Pharmaceuticals Recent Development
11.9 Capricor Therapeutics
11.9.1 Capricor Therapeutics Company Details
11.9.2 Capricor Therapeutics Business Overview
11.9.3 Capricor Therapeutics Cardiomyopathy Medication Introduction
11.9.4 Capricor Therapeutics Revenue in Cardiomyopathy Medication Business (2016-2021)
11.9.5 Capricor Therapeutics Recent Development
11.10 MyoKardia
11.10.1 MyoKardia Company Details
11.10.2 MyoKardia Business Overview
11.10.3 MyoKardia Cardiomyopathy Medication Introduction
11.10.4 MyoKardia Revenue in Cardiomyopathy Medication Business (2016-2021)
11.10.5 MyoKardia Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Cardiomyopathy Medication Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Anticoagulants
Table 3. Key Players of Antiarrhythmics
Table 4. Key Players of Anti-Hypertensives
Table 5. Key Players of Cardiac Glycosides
Table 6. Key Players of Others
Table 7. Global Cardiomyopathy Medication Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Cardiomyopathy Medication Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Cardiomyopathy Medication Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Cardiomyopathy Medication Market Share by Regions (2016-2021)
Table 11. Global Cardiomyopathy Medication Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Cardiomyopathy Medication Market Share by Regions (2022-2027)
Table 13. Cardiomyopathy Medication Market Trends
Table 14. Cardiomyopathy Medication Market Drivers
Table 15. Cardiomyopathy Medication Market Challenges
Table 16. Cardiomyopathy Medication Market Restraints
Table 17. Global Cardiomyopathy Medication Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Cardiomyopathy Medication Market Share by Players (2016-2021)
Table 19. Global Top Cardiomyopathy Medication Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Cardiomyopathy Medication as of 2020)
Table 20. Ranking of Global Top Cardiomyopathy Medication Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Cardiomyopathy Medication Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Cardiomyopathy Medication Product Solution and Service
Table 24. Date of Enter into Cardiomyopathy Medication Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Cardiomyopathy Medication Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Cardiomyopathy Medication Revenue Market Share by Type (2016-2021)
Table 28. Global Cardiomyopathy Medication Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Cardiomyopathy Medication Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Cardiomyopathy Medication Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Cardiomyopathy Medication Revenue Market Share by Application (2016-2021)
Table 32. Global Cardiomyopathy Medication Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Cardiomyopathy Medication Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Cardiomyopathy Medication Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Cardiomyopathy Medication Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Cardiomyopathy Medication Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Cardiomyopathy Medication Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Cardiomyopathy Medication Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Cardiomyopathy Medication Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Cardiomyopathy Medication Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Cardiomyopathy Medication Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Cardiomyopathy Medication Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Cardiomyopathy Medication Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Cardiomyopathy Medication Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Cardiomyopathy Medication Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Cardiomyopathy Medication Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Cardiomyopathy Medication Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Cardiomyopathy Medication Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Cardiomyopathy Medication Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Cardiomyopathy Medication Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Cardiomyopathy Medication Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Cardiomyopathy Medication Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Cardiomyopathy Medication Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Cardiomyopathy Medication Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Cardiomyopathy Medication Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Cardiomyopathy Medication Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Cardiomyopathy Medication Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Cardiomyopathy Medication Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Cardiomyopathy Medication Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Cardiomyopathy Medication Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Cardiomyopathy Medication Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Cardiomyopathy Medication Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Cardiomyopathy Medication Market Size by Country (2022-2027) & (US$ Million)
Table 64. Pfizer Company Details
Table 65. Pfizer Business Overview
Table 66. Pfizer Cardiomyopathy Medication Product
Table 67. Pfizer Revenue in Cardiomyopathy Medication Business (2016-2021) & (US$ Million)
Table 68. Pfizer Recent Development
Table 69. Roche Company Details
Table 70. Roche Business Overview
Table 71. Roche Cardiomyopathy Medication Product
Table 72. Roche Revenue in Cardiomyopathy Medication Business (2016-2021) & (US$ Million)
Table 73. Roche Recent Development
Table 74. Sanofi Company Details
Table 75. Sanofi Business Overview
Table 76. Sanofi Cardiomyopathy Medication Product
Table 77. Sanofi Revenue in Cardiomyopathy Medication Business (2016-2021) & (US$ Million)
Table 78. Sanofi Recent Development
Table 79. AstraZeneca Company Details
Table 80. AstraZeneca Business Overview
Table 81. AstraZeneca Cardiomyopathy Medication Product
Table 82. AstraZeneca Revenue in Cardiomyopathy Medication Business (2016-2021) & (US$ Million)
Table 83. AstraZeneca Recent Development
Table 84. Merck Company Details
Table 85. Merck Business Overview
Table 86. Merck Cardiomyopathy Medication Product
Table 87. Merck Revenue in Cardiomyopathy Medication Business (2016-2021) & (US$ Million)
Table 88. Merck Recent Development
Table 89. Teva Pharmaceutical Company Details
Table 90. Teva Pharmaceutical Business Overview
Table 91. Teva Pharmaceutical Cardiomyopathy Medication Product
Table 92. Teva Pharmaceutical Revenue in Cardiomyopathy Medication Business (2016-2021) & (US$ Million)
Table 93. Teva Pharmaceutical Recent Development
Table 94. Johnson & Johnson Company Details
Table 95. Johnson & Johnson Business Overview
Table 96. Johnson & Johnson Cardiomyopathy Medication Product
Table 97. Johnson & Johnson Revenue in Cardiomyopathy Medication Business (2016-2021) & (US$ Million)
Table 98. Johnson & Johnson Recent Development
Table 99. PhaseBio Pharmaceuticals Company Details
Table 100. PhaseBio Pharmaceuticals Business Overview
Table 101. PhaseBio Pharmaceuticals Revenue in Cardiomyopathy Medication Business (2016-2021) & (US$ Million)
Table 102. PhaseBio Pharmaceuticals Recent Development
Table 103. Capricor Therapeutics Company Details
Table 104. Capricor Therapeutics Business Overview
Table 105. Capricor Therapeutics Cardiomyopathy Medication Product
Table 106. Capricor Therapeutics Revenue in Cardiomyopathy Medication Business (2016-2021) & (US$ Million)
Table 107. Capricor Therapeutics Recent Development
Table 108. MyoKardia Company Details
Table 109. MyoKardia Business Overview
Table 110. MyoKardia Cardiomyopathy Medication Product
Table 111. MyoKardia Revenue in Cardiomyopathy Medication Business (2016-2021) & (US$ Million)
Table 112. MyoKardia Recent Development
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Cardiomyopathy Medication Market Share by Type: 2020 VS 2027
Figure 2. Anticoagulants Features
Figure 3. Antiarrhythmics Features
Figure 4. Anti-Hypertensives Features
Figure 5. Cardiac Glycosides Features
Figure 6. Others Features
Figure 7. Global Cardiomyopathy Medication Market Share by Application: 2020 VS 2027
Figure 8. Hospitals Case Studies
Figure 9. Clinics Case Studies
Figure 10. Homecare Case Studies
Figure 11. Others Case Studies
Figure 12. Cardiomyopathy Medication Report Years Considered
Figure 13. Global Cardiomyopathy Medication Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 14. Global Cardiomyopathy Medication Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 15. Global Cardiomyopathy Medication Market Share by Regions: 2020 VS 2027
Figure 16. Global Cardiomyopathy Medication Market Share by Regions (2022-2027)
Figure 17. Global Cardiomyopathy Medication Market Share by Players in 2020
Figure 18. Global Top Cardiomyopathy Medication Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Cardiomyopathy Medication as of 2020
Figure 19. The Top 10 and 5 Players Market Share by Cardiomyopathy Medication Revenue in 2020
Figure 20. Global Cardiomyopathy Medication Revenue Market Share by Type (2016-2021)
Figure 21. Global Cardiomyopathy Medication Revenue Market Share by Type (2022-2027)
Figure 22. North America Cardiomyopathy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. North America Cardiomyopathy Medication Market Share by Type (2016-2027)
Figure 24. North America Cardiomyopathy Medication Market Share by Application (2016-2027)
Figure 25. North America Cardiomyopathy Medication Market Share by Country (2016-2027)
Figure 26. United States Cardiomyopathy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Canada Cardiomyopathy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Cardiomyopathy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe Cardiomyopathy Medication Market Share by Type (2016-2027)
Figure 30. Europe Cardiomyopathy Medication Market Share by Application (2016-2027)
Figure 31. Europe Cardiomyopathy Medication Market Share by Country (2016-2027)
Figure 32. Germany Cardiomyopathy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. France Cardiomyopathy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. U.K. Cardiomyopathy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Italy Cardiomyopathy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Russia Cardiomyopathy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Nordic Cardiomyopathy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Cardiomyopathy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific Cardiomyopathy Medication Market Share by Type (2016-2027)
Figure 40. Asia-Pacific Cardiomyopathy Medication Market Share by Application (2016-2027)
Figure 41. Asia-Pacific Cardiomyopathy Medication Market Share by Region (2016-2027)
Figure 42. China Cardiomyopathy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Japan Cardiomyopathy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. South Korea Cardiomyopathy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Southeast Asia Cardiomyopathy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. India Cardiomyopathy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Australia Cardiomyopathy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Cardiomyopathy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America Cardiomyopathy Medication Market Share by Type (2016-2027)
Figure 50. Latin America Cardiomyopathy Medication Market Share by Application (2016-2027)
Figure 51. Latin America Cardiomyopathy Medication Market Share by Country (2016-2027)
Figure 52. Mexico Cardiomyopathy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Brazil Cardiomyopathy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Cardiomyopathy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa Cardiomyopathy Medication Market Share by Type (2016-2027)
Figure 56. Middle East & Africa Cardiomyopathy Medication Market Share by Application (2016-2027)
Figure 57. Middle East & Africa Cardiomyopathy Medication Market Share by Country (2016-2027)
Figure 58. Turkey Cardiomyopathy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Saudi Arabia Cardiomyopathy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. UAE Cardiomyopathy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. Pfizer Revenue Growth Rate in Cardiomyopathy Medication Business (2016-2021)
Figure 62. Roche Revenue Growth Rate in Cardiomyopathy Medication Business (2016-2021)
Figure 63. Sanofi Revenue Growth Rate in Cardiomyopathy Medication Business (2016-2021)
Figure 64. AstraZeneca Revenue Growth Rate in Cardiomyopathy Medication Business (2016-2021)
Figure 65. Merck Revenue Growth Rate in Cardiomyopathy Medication Business (2016-2021)
Figure 66. Teva Pharmaceutical Revenue Growth Rate in Cardiomyopathy Medication Business (2016-2021)
Figure 67. Johnson & Johnson Revenue Growth Rate in Cardiomyopathy Medication Business (2016-2021)
Figure 68. PhaseBio Pharmaceuticals Revenue Growth Rate in Cardiomyopathy Medication Business (2016-2021)
Figure 69. Capricor Therapeutics Revenue Growth Rate in Cardiomyopathy Medication Business (2016-2021)
Figure 70. MyoKardia Revenue Growth Rate in Cardiomyopathy Medication Business (2016-2021)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed

以下、関連資料のご紹介

世界の拡張型心筋症用治療薬市場規模・現状・予測（2021年-2027年）

Global Dilated Cardiomyopathy Therapeutics Market Size, Status and Forecast 2021-2027
QFJ1-4137 2021年6月 105Pages
QYResearch社発行の本調査レポートでは、拡張型心筋症用治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（薬剤クラス、植込み型デバイス、パイプライン分析）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、欧州、...

世界の拡張型心筋症治療薬市場規模・現状・予測（2021年-2027年）

Global Dilated Cardiomyopathy Therapeutic Market Size, Status and Forecast 2021-2027
QFJ1-4136 2021年6月 107Pages
QYResearch社発行の本調査レポートでは、拡張型心筋症治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（アルドステロン拮抗薬、アンジオテンシン変換酵素（ACE）阻害薬、アンジオテンシンII受容体拮抗薬（ARB）、ベータ遮断薬）、用途別市場...

世界のCOPD用治療薬市場規模・現状・予測（2021年-2027年）

Global COPD Medication Market Size, Status and Forecast 2021-2027
QFJ1-5675 2021年6月 97Pages
QYResearch社発行の本調査レポートでは、COPD用治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（短時間作用型気管支拡張薬、コルチコステロイド、メチルキサンチン、長時間作用型気管支拡張薬、併用薬）、用途別市場規模（病院、診療所、薬局、...

世界の投薬＆包装システム市場規模・現状・予測（2021年-2027年）

Global Medication Dispensing and Packaging Systems Market Size, Status and Forecast 2021-2027
QFJ1-4485 2021年6月 100Pages
QYResearch社発行の本調査レポートでは、投薬＆包装システムの世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（キャニスター100個以下、101〜300個、キャニスター300個以上）、用途別市場規模（小売薬局、病院薬局、介護薬局）、主要地域別市場...

世界の注射式鎮痛薬市場規模・現状・予測（2021年-2027年）

Global Injectable Pain Medication Market Size, Status and Forecast 2021-2027
QFJ1-4373 2021年6月 95Pages
QYResearch社発行の本調査レポートでは、注射式鎮痛薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（非ステロイド性抗炎症薬（NSAID）、中枢作用性鎮痛薬）、用途別市場規模（病院、クリニック、リカバリーセンター）、主要地域別市場規模（北米、...

世界の喘息/COPD併用薬市場規模・現状・予測（2021年-2027年）

Global Asthma/COPD Combination Medication Market Size, Status and Forecast 2021-2027
QFJ1-5601 2021年6月 95Pages
QYResearch社発行の本調査レポートでは、喘息/COPD併用薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（ブデソニド、LAMA / LABAコンボ、フルチカゾン/サルメテロール）、用途別市場規模（中等度COPD、重度COPD、喘息）、主要...

世界の安全投薬用遺伝子検査市場規模・現状・予測（2021年-2027年）

Global Genetic Testing for Safe Medication Market Size, Status and Forecast 2021-2027
QFJ1-4254 2021年6月 98Pages
QYResearch社発行の本調査レポートでは、安全投薬用遺伝子検査の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（口腔粘膜コレクション、FTA血液サンプルコレクション）、用途別市場規模（病院、診療所）、主要地域別市場規模（北米、アメリカ、欧州、ア...

世界の抗糖尿病薬市場規模・現状・予測（2021年-2027年）

Global Anti-diabetic Medication Market Size, Status and Forecast 2021-2027
QFJ1-5584 2021年6月 97Pages
QYResearch社発行の本調査レポートでは、抗糖尿病薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（経口、注射、その他）、用途別市場規模（糖尿病予防・治療、肥満治療、心臓血管保護、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日...

世界のペット用医薬品市場規模・現状・予測（2021年-2027年）

Global Pet Medication Market Size, Status and Forecast 2021-2027
QFJ1-5942 2021年6月 123Pages
QYResearch社発行の本調査レポートでは、ペット用医薬品の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（抗生物質、抗真菌剤、ノミ製品）、用途別市場規模（猫、犬、馬、魚、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓...

世界の歯科用医薬品市場規模・現状・予測（2021年-2027年）

Global Medication for Dental Market Size, Status and Forecast 2021-2027
QFJ1-5845 2021年6月 116Pages
QYResearch社発行の本調査レポートでは、歯科用医薬品の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（オピオイド、NSAID、OTC鎮痛薬）、用途別市場規模（病院、ドラッグストア、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日...

世界の抗糖尿病薬市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Anti-diabetic Medication Market The global Anti-diabetic Medication market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and high data integrity, the …
世界の拡張型心筋症用治療薬市場規模・現状・予測（2021年-2027年） Dilated cardiomyopathy (DCM) is a condition in which the heart's ability to pump blood is decreased because the heart's main pumping chamber, the left ventricle, is enlarged and weakened. In some cases, it prevents the heart from relaxing and filling with blood as it should. Market Analysis and Insi…
世界の拡張型心筋症治療薬市場規模・現状・予測（2021年-2027年） Dilated cardiomyopathy (DCM) is characterized by LV (left ventricular) or biventricular systolic dysfunction and dilation, not explained by abnormal loading conditions or coronary artery disease. Market Analysis and Insights: Global Dilated Cardiomyopathy Therapeutic Market The global Dilated Cardio…
世界の注射式鎮痛薬市場規模・現状・予測（2021年-2027年） Analgesics refer to drugs that can partially or completely relieve pain. There are two types of non-steroidal anti-inflammatory drugs and central analgesics. The latter is currently mainly used in the treatment of cancer pain, and can also be used for short-term postoperative pain relief. Market Ana…
世界のCOPD用治療薬市場規模・現状・予測（2021年-2027年） Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease that causes obstructed airflow from the lungs. Symptoms include breathing difficulty, cough, mucus (sputum) production and wheezing. It's typically caused by long-term exposure to irritating gases or particulate matt…